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Abstract
Background: The association between TGF-β1 levels and long-term major adverse cardiovascular events (MACE) in
patients with coronary artery disease (CAD) is controversial. No study specifically addressed patients with CAD and
diabetes mellitus (DM). The association between TGF-β1 levels and long-term major adverse cardiovascular events
(MACE) in patients with coronary artery disease (CAD) is controversial. No study specifically addressed patients with
CAD and diabetes mellitus (DM).
Methods: Patients (n = 135, 30–80 years) referred for coronary angiography were submitted to clinical and laboratory
evaluation, and the coronary angiograms were evaluated by two operators blinded to clinical characteristics. CAD was
defined as the presence of a 70% stenosis in one major coronary artery, and DM was characterized as a fasting glycemia
> 126 mg/dl or known diabetics (personal history of diabetes or previous use of anti-hyperglycemic drugs or insulin).
Based on these criteria, study patients were classified into four groups: no DM and no CAD (controls, C n = 61), DM
without CAD (D n = 23), CAD without DM (C-CAD n = 28), and CAD with DM (D-CAD n = 23). Baseline differences
between the 4 groups were evaluated by the χ2 test for trend (categorical variables) and by ANOVA (continuous
variables, post-hoc Tukey). Patients were then followed-up during two years for the occurrence of MACE (cardiac death,
stroke, myocardial infarction or myocardial revascularization). The association of candidate variables with the occurrence
of 2-year MACE was assessed by univariate analysis.
Results: The mean age was 58.2 ± 0.9 years, and 51% were men. Patients with CAD had a higher mean age (p = 0.011)
and a higher percentage were male (p = 0.040). There were no significant baseline differences between the 4 groups
regarding hypertension, smoking status, blood pressure levels, lipid levels or inflammatory markers. TGF-β1 was similar
between patients with or without CAD or DM (35.1 ×/÷ 1.3, 33.6 ×/÷ 1.6, 33.9 ×/÷ 1.4 and 31.8 ×/÷ 1.4 ng/ml in C, D,
C-CAD and D-CAD, respectively, p = 0.547). In the 2-year follow-ip, independent predictors of 2-year MACE were age
(p = 0.007), C-reactive protein (p = 0.048) and systolic blood pressure (p = 0.008), but not TGF-β1.
Conclusion: Serum TGF-β1 was not associated with CAD or MACE occurrence in patients with or without DM.
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Background
Atherosclerosis is related to lipid abnormalities, platelet
activation, thrombosis, endothelial dysfunction, inflam-
mation, oxidative stress and altered matrix metabolism
[1], among other disturbances. Several risk factors are
known to play a role in this intricate cascade, and diabetes
mellitus (DM) is associated with a 3-fold increase in the
risk of death or myocardial infarction due to coronary
artery disease (CAD) [2]. There is considerable debate as
to whether the pathogenesis of atherosclerosis in diabetics
is different, or whether DM simply accelerates this proc-
ess. The identification of specific pathophysiologic fea-
tures in diabetics could lead to a targeted approach to
control disease progression in this set of patients.
A number of inflammatory cytokines mediate atheroscle-
rosis, and TGF-β1 modulates important events like macro-
phage and fibroblast chemotaxis, suppression of
lymphocyte function, collagen synthesis and stimulation
of extracellular matrix synthesis [3-7]. Nikol et al demon-
strated increased expression of TGF-β1 in human athero-
sclerotic plaques, and it was subsequently demonstrated
that diabetic patients presenting with an acute myocardial
infarction revealed decreased smooth muscle cells
(SMCs), increased macrophages and TGF-β1 into the cul-
prit lesion [8,9].
Other studies showed that reduced plasma levels of TGF-
β1 in patients with angiographically proven CAD [10-12],
and TGF-β1 levels were also found to be inversely related
to the extend of coronary disease [13]. Tashiro et al
observed that lower TGF-β1 levels were associated with
increased risk of long-term major adverse cardiovascular
events (MACE), suggesting that plasma levels of this
citokyne may have prognostic significance in patients
with CAD [14]. However, other studies failed to demon-
strate an association between TGF-β1 and atherosclerotic
disease [15], and no study was specifically addressed to
diabetic patients. The aim of the present study is to evalu-
ate the association between serum TGF-β1 and CAD in
patients with DM, and its influence in long-term MACE
incidence.
Methods
Subjects
Patients included were referred for coronary angiography
by their attending physicians between December 2002
and December 2003. Inclusion criteria were age between
30 and 80 years, chest pain and documented myocardial
ischemia in the non-invasive evaluation. The exclusion
criteria were acute myocardial infarction in the last 60
days, previous heart transplantation or revascularization
procedure, use of anticoagulants, known malignant neo-
plasia and haemodialysis. Each subject gave written
informed consent and the study protocol was approved by
the Hospital Ethics Committee.
On the day of the coronary angiography, a clinical ques-
tionnaire was applied and a physical examination was
performed. A 12 h-fasting blood sample collection and a
morning spot urine analysis were done before coronary
angiography. Blood samples were collected in tubes with-
out conservants, kept at room temperature for 3 hours
and then stored at 4°C overnight. Serum aliquots were
obtained after centrifugation (1000 G for 40 minutes at
4°C) and stored at -80°C until assay.
Based on the clinical history and on coronary artery dis-
ease severity, subjects were divided into four groups: no
diabetes and no coronary artery disease (controls, C), dia-
betes and no coronary artery disease (D), coronary artery
disease and no diabetes (C-CAD) and coronary artery dis-
ease and diabetes (D-CAD). Diabetes mellitus was
defined as serum fasting glucose > 126 mg/dl or known
diabetics, as evaluated by a personal history of diabetes or
previous use of anti-hyperglycemic drugs or insulin.
Patients were followed-up either by clinical evaluation in
an outpatient clinic, by interview with the attending phy-
sician or by telephone contact. The incidence of major
adverse cardiovascular events (MACE) in the follow-up
period was recorded. MACE was defined as the occurrence
of cardiac death, ischemic stroke, myocardial infarction
(AMI) or the need for a revascularization procedure
(either percutaneous or surgical). Myocardial infarction
was defined according to the criteria of the American Col-
lege of Cardiology [16].
Measurements of TGF-β1 levels
For the measurement of serum active TGF-β1 levels we
used a solid phase ELISA designed to measure biologically
active TGF-β1 (R&D Systems, Abingdon, UK). On the day
of the assay, serum samples (0.5 ml) were acidified to a
pH of 2–3 with 100 µl 1N HCL for 10 minutes to activate
latent TGF-β, and then re-neutralized to pH 7–8 with 100
µl 1.2N NaOH/0.5 M HEPES. Results were expressed in
ng/ml. The mean intra and inter assay coefficients of vari-
ation were respectively 2.0% and 13.1%.
Biochemical analysis
Fasting blood samples were obtained for glucose, total
cholesterol, high-density cholesterol, triglycerides, creati-
nine, and laboratory measurements were performed using
automated enzymatic commercial kits (Roche, Manhein,
GE). Fibrinogen was evaluated on a Fibrintimer II (Dade
Behring Inc., Newark, Marburg, Germany) and processed
in the auto-analyser (CA-540, Sysmex). Urinary albumin
was evaluated in morning spot urine samples by immu-
noturbidimetry (antiserum to human albumin, DadeCardiovascular Diabetology 2007, 6:19 http://www.cardiab.com/content/6/1/19
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Behring Inc., Marburg, Germany) and the absolute con-
centration was considered. Levels higher than 17 mg/l
were considered microalbuminuria. The concentration of
low-density cholesterol (LDL-c) was calculated with
Friedewald's formula. Serum insulin was determined by
enzyme immunoassay commercial kits (Abbot-Murex,
Park, IL, USA,), HbA1c by immunoturbidimetry (Roche,
Manhein, GE) and ultrasensitive C-reactive protein (CRP)
by nephelometry (nephelometer BN100, Dade Behring
Inc., Marburg, Germany). Insulin resistance was assessed
by the HOMA-IR (homeostasis model assessment of insu-
lin resistance) in individuals who were not on anti-dia-
betic agents or insulin. The HOMA-IR is the product of the
fasting plasma glucose (mmol/l) by plasma insulin (µ/
ml), divided by a constant (22.5) [17].
Coronary angiography
All coronary angiographies were performed at the Cathe-
terization Laboratory of our institution according to
standard routines. The coronary angiograms were evalu-
ated by two experienced interventional cardiologists, una-
ware of the patients' glucose tolerance status.
Angiographic analyses were performed in two orthogonal
views with a validated digital quantitative coronary angi-
ography system (Siemens Axiom Artis equipment;
Munich, Germany). Significant coronary artery disease
was considered to be present if an internal luminal nar-
rowing greater than 70% was detected in at least one
major coronary artery.
Statistical analysis
Categorical variables were expressed as percentiles; con-
tinuous variables were expressed as the mean ± standard
error of mean (SEM), unless otherwise specified. Differ-
ences between the four groups studied were evaluated by
the χ2 test for trend (categorical variables) and by ANOVA
(continuous variables, post-hoc Tukey). TGF-β1 data were
log-transformed before analysis. For all tests, a P value ≤
0.05 was considered to be statistically significant. The
association of candidate variables with the occurrence of
2-year MACE was assessed by univariate analysis, and
those with a p ≥ 0.20 were included in a multiple regres-
sion logistic model.
Results
The population of this study was comprised of 135
patients with a mean age of 58.2 ± 0.9 (30–80) years, of
whom 51.1% were men. Patients with diabetes (D and D-
CAD) had significantly more CAD than patients without
diabetes (C and C-CAD; 50% vs 31.5%, p = 0.035). Table
1 shows baseline clinical characteristics of the studied
subjects. Patients with CAD (D-CAD and C-CAD) had a
higher mean age (p = 0.011) and a higher percentage were
male (p = 0.040) than those without CAD. Body mass
index was significantly higher in D vs the other groups.
The other clinical characteristics assessed (hypertension
and familial CAD history, percentage of patients who
were smokers, statin/ASA/ACEI users, physically active
and the mean systolic and diastolic blood pressure) were
not statistically different between the four groups of
patients. We observed a low overall use of statin in all
groups, which could be related to the lack of an estab-
lished previous diagnosis of CAD in many patients.
Table 2 shows baseline laboratory characteristics of the
studied subjects. As expected, diabetics had higher fasting
plasma glucose (p < 0.001), HbA1c (p < 0.001) and were
more insulin resistant (higher HOMA-IR, p = 0.006). Lip-
ids, fibrinogen, CRP and insulin levels were similar
between the four groups studied.
Figure 1 shows the baseline levels of serum TGF-β1. It is
shown that they are similar between the studied groups,
with or without angiographically proven coronary artery
disease, diabetics or not.
Clinical follow-up was completed in 123 patients
(91.2%), and the mean follow-up period was 27.2 ± 6
months. From the possible associated variables evaluated,
HbA1c, CRP, systolic blood pressure and angiographically
proven CAD were significantly different in patients who
developed MACE as compared with those who did not.
These data are shown in Table 3. However, after multivar-
iate analysis of candidate variables associated with 2-year
MACE, those that were significantly associated with the
endpoint studied were age (p = 0.007), CRP (p = 0.048)
and systolic blood pressure (p = 0.008). Serum TGF-β1
was not significantly associated with MACE. These data
are shown in table 4.
Discussion
The present study did not demonstrate a significant asso-
ciation between serum TGF-β1 levels and CAD in diabetic
patients, or in controls. The independent predictors of 2-
year MACE were increased age, C-reactive protein and
systolic blood pressure, but not serum TGF-β1.
TGF-β1 biological activities include inhibition of cell pro-
liferation, regulation of cell differentiation, stimulation of
cell adhesion, extracellular matrix deposition [18,19] and
inhibition of the growth and proliferation of vascular
smooth cells [4], findings consistent with an anti-athero-
genic role for TGF-β1. It also has a role in the regulation
of the inflammatory process in the atherosclerotic plaque,
being secreted by several cell types, including regulatory
Th2 cells. It acts by antagonizing Th1 cell IF-gama produc-
tion, an inflammatory response inductor [6]. Indeed,
TGF-β1 plays a much more important role in the down-
regulation of Th1 cell inflammatory response than in the
atherosclerotic lesion size. Thus, large plaques do not nec-Cardiovascular Diabetology 2007, 6:19 http://www.cardiab.com/content/6/1/19
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essarily mean a more advanced inflammatory process.
According to that particular rationale TGF-β1 is a much
more important inflammatory marker than an atheroscle-
rotic marker, which agrees with the present data.
Several clinical studies have already demonstrated that
patients with advanced atherosclerosis present lower
plasma concentrations of TGF-β1 than those without
CAD [11-14,20]. Conversely, Border and Ruoslahti
showed that TGF-β1 could enhance atherogenesis by
mediating excessive extracellular matrix accumulation
[21] and by down-regulating thrombomodulin, promot-
ing thrombogenesis at the sites of vessel wall injury, where
it is released from platelets, smooth muscle cells and
monocytes [22]. This is in accordance with clinical studies
which showed high levels of active TGF-β1 levels in CAD
[15]. However, none of the data mentioned above specif-
ically addressed subjects with diabetes, which was the sub-
ject of the pesent work.
Although not classifying patients as diabetics or not,
Wang et al demonstrated a positive correlation between
active and total TGF-β1 levels and plasma glucose. In vitro
studies showed that hyperglycemia induces TGF-β1 pro-
Table 1: Clinical characteristics of the studied patients
C D C-CAD D-CAD P
N 61 23 28 23
Mean age (years) 55.3 ± 1.4 58.2 ± 1.6 61.8 ± 2.0# 61.7 ± 2.0# 0.011
BMI (kg/m2) 28.07 ± 0.7 31.04 ± 1.0* 26.44 ± 0.8 27.27 ± 0.9 0.008
Male (%) 41.0 43.5 64.3 † 69.3 † 0.040
Hypertension history 
(%)
63.9 91.3 69.2 73.9 0.100
Familial CAD history 
(%)
68.3 63.6 59.3 69.6 0.831
Smoking (%) 31.7 30.4 23.1 26.1 0.857
Statin users (%) 18.0 8.7 25.0 17.4 0.512
AAS users (%) 63.3 82.6 71.4 78.3 0.284
ACEI users (%) 29.5 50.0 33.3 47.8 0.223
Physically active (%) 18.3 34.8 39.3 30.4 0.159
SBP (mmHg) 141.8 ± 4.7 134.4 ± 3.4 145.8 ± 7.3 140.2 ± 2.9 0.422
DBP (mmHg) 80.7 ± 2.5 84.3 ± 2.3 86.1 ± 4.5 87.0 ± 1.7 0.365
Data are means ± SEM or %
C: no diabetes and no coronary artery disease, D: diabetes and no coronary artery disease, C-CAD: coronary artery disease and no diabetes and 
D-CAD: coronary artery disease and diabetes; BMI: body mass index; ACEI: angiotensin-converting enzyme inhibitors; SBP: systolic blood pressure; 
DBP: diastolic blood pressure.
* P < 0.05 vs C-CAD; # P < 0.05 vs C; † P < 0.05 vs C and D
Table 2: Laboratory characteristics of the studied groups
C D C-CAD D-CAD P
N 61 23 28 23
Plasma glucose (mg/dl) 93.1 ± 1.4 143.6 ± 14.5* 96.2 ± 2.2 141.8 ± 11.7* <0.001
HbA1c (%) 5.71 ± 0.05 6.67 ± 0.35* 5.72 ± 0.06 7.08 ± 0.33* <0.001
TC (mg/dl) 194.4 ± 5.5 201.7 ± 10.2 213.5 ± 7.9 219.6 ± 10.3 0.080
LDL-c (mg/dl) 111.9 ± 4.3 121.3 ± 8.3 126.2 ± 6.3 129.2 ± 8.2 0.144
HDL-c (mg/dl) 49.9 ± 1.5 46.6 ± 1.9 44.5 ± 2.2 45.4 ± 1.9 0.116
Non HDL-c (mg/dl) 142.7 ± 5.6 155.1 ± 9.3 168.4 ± 7.8# 174.2 ± 9.6# 0.009
TG (mg/dl) 160.9 ± 13.7 169.1 ± 15.8 216.4 ± 31.4 224.9 ± 30.7 0.082
Fibrinogen (mg/dl) 348.2 ± 11.4 335.7 ± 19.5 355.9 ± 17.4 353.2 ± 21.8 0.883
CRP (mg/l) 7.63 ± 1.27 4.48 ± 1.13 7.21 ± 2.61 8.57 ± 2.00 0.551
Insulin levels (µU/ml) 12.92 ± 1.3 21.25 ± 6.9 12.1 ± 1.4 17.6 ± 2.6 0.122
HOMA-IR 3.09 ± 0.34 9.06 ± 3.63* 2.99 ± 0.39 6.42 ± 1.16 0.006
TGF B (ng/ml) 35,1 ×/÷ 1,3 33,6 ×/÷ 1,6 33,9 ×/÷ 1,4 31,8 ×/÷ 1,4 0,547
Data are means ± SEM or n (%)
C: no diabetes and no coronary artery disease, D: diabetes and no coronary artery disease, C-CAD: coronary artery disease and no diabetes and 
D-CAD: coronary artery disease and diabetes; HbA1c: glycated haemoglobin; TC: total cholesterol; LDL-c: low-density lipoprotein cholesterol; 
HDL-c: high-density lipoprotein cholesterol; TG: triglycerides; HOMA-IR: model of homeostatic evaluation.
*P < 0.001 vs C and C-CAD; # P < 0.05 vs CCardiovascular Diabetology 2007, 6:19 http://www.cardiab.com/content/6/1/19
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duction in endothelial cells [23] and in mesangial cells of
the kidney [24]. We suggest that TGF-β1 levels of our dia-
betic patients are raised in consequence of hyperglycemia,
since their plasma glucose levels and HbA1c were higher
than those of non-diabetics. Possibly in the diabetic pop-
ulation the hyperglycemia counteracts the atherosclerosis
TGF-β1 reducing effect, masking the discriminatory role
of this cytokine as found by other studies in non-diabetic
subjects. Moreover, as aspirin medication correlates with
an increase in active TGF-β1 concentration [11], the high
percentage of subjects using the drug (71%) also could
have masked its discriminatory role.
We could not stratify patients according to CAD severity,
because of the small number of subjects in each studied
group. It is possible that the relevance of TGF-β1 in dis-
criminating CAD could only be observed in severe dis-
ease, as shown by other authors in CAD [13,25,26] and
peripheral artery disease [27]. Using clinical criteria for
the diagnosis of significant atherosclerotic vascular dis-
ease in hemodialysis patients, Stefoni et al showed
reduced survival in a 24 month follow-up of patients with
lower TGF-β1 levels at the beginning of the study [25].
Tashiro et al provided the unique evidence in literature
that plasma concentrations of TGF-β1 have a prognostic
significance in patients with angiographically-proven
CAD, in a limited number of patients followed up for a
mean period of 979 days [14]. This study did not show
plasma TGF-β1 measurements in the patients' follow-up,
but these values are supposed to be stable, according to
the authors. Although the same drawbacks could be
applied to the present study, we showed a different result,
and therefore we question the significance of those find-
ings.
A potential limitation of the present study could be the
stability of TGF-β1 in peripheral blood. In a recent work,
we showed that plasma TGF-β1 is quite stable in patients
with diabetes and nephropathy, no changes being
detected by strict 12-week blood pressure control despite
a significant fall in urinary TGF-β1 levels [28]. Although it
is possible that minor changes in TGF-β1 production from
endothelial cells could not be detectable in serum where
platelet TGF-β1 is abundant, greater decreases, as
expected, are unlikely. Other possible limitation of the
present study was the number of subjects studied, that did
not permit to stratify the sample by age, searching for pos-
sible age-related physiological decrease in TGF-β1 levels
described by other authors [29].
Conclusion
In conclusion, serum TGF-β1 was not associated with
CAD or MACE occurrence in diabetic patients. The role of
TGF-β1 in atherosclerosis associated with diabetes needs
further evaluation by means of longer prospective studies
with a large number of patients.
Table 4: Multivariate analysis of candidate variables associated 
with 2-year MACE
Variable OR CI 95% Waldχ2 β p
Age (years) 0.936 0.89–0.98 7.293 -0.066 0.007
TGF-β (ng/ml) 0.993 0.95–1.03 0.096 -0.007 0.756
HbA1c (%) 1.801 0.99–3.24 3.832 0.589 0.050
CRP (mg/dl) 1.059 1.00–1.12 3.927 0.057 0.048
SBP (mmHg) 1.035 1.00–1.06 7.006 0.034 0.008
CAD (presence or 
absence)
1.857 0.68–5.01 1.494 0.619 0.222
Constant 3.307 -5.230 0.069
CI: Confidence Interval; SBP: systolic blood pressure; CAD: coronary 
artery disease
Table 3: Clinical, angiographic and laboratory characteristics of 
the patient population (n = 123) according to the occurrence of 
MACE in the 2-year follow-up
MACE No MACE P
Age (years) 57.48 ± 1.5 60.77 ± 1.1 0.156
Male sex (%) 41.5 58.5 0.861
TGF-β1 (ng/ml) 33.82 ± 1.5 37.08 ± 1.5 0.14
HbA1c (%) 6.31 ± 0.2 5.91 ± 0.09 0.001
CRP (mg/dl) 9.14 ± 1.8 5.51 ± 0.8 <0.001
SBP (mmHg) 144.1 ± 3.4 136.7 ± 2.0 0.021
CAD % 28.9 71.1 0.025
SBP: systolic blood pressure; CAD: coronary artery disease
Serum TGF-β1 in the four groups of patients studied Figure 1
Serum TGF-β1 in the four groups of patients studied. 
C: no diabetes and no coronary artery disease (open bar), D: 
diabetes and no coronary artery disease (dark bar), C-CAD: 
coronary artery disease and no diabetes (gray bar) and D-
CAD: coronary artery disease and diabetes (dashed bar). 
Data are expressed as geometric mean ×/÷ tolerance factor. 
p = 0.743 (ANOVA).Cardiovascular Diabetology 2007, 6:19 http://www.cardiab.com/content/6/1/19
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